ATE448775T1 - Rifalazil zur behandlung von infektionen mit clostridium difficile - Google Patents
Rifalazil zur behandlung von infektionen mit clostridium difficileInfo
- Publication number
- ATE448775T1 ATE448775T1 AT03749288T AT03749288T ATE448775T1 AT E448775 T1 ATE448775 T1 AT E448775T1 AT 03749288 T AT03749288 T AT 03749288T AT 03749288 T AT03749288 T AT 03749288T AT E448775 T1 ATE448775 T1 AT E448775T1
- Authority
- AT
- Austria
- Prior art keywords
- rifalazil
- clostridium difficile
- treatment
- difficile infections
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40687302P | 2002-08-29 | 2002-08-29 | |
US44457003P | 2003-02-03 | 2003-02-03 | |
PCT/US2003/027305 WO2004019907A1 (en) | 2002-08-29 | 2003-08-29 | Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448775T1 true ATE448775T1 (de) | 2009-12-15 |
Family
ID=31981443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03749288T ATE448775T1 (de) | 2002-08-29 | 2003-08-29 | Rifalazil zur behandlung von infektionen mit clostridium difficile |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040106590A1 (de) |
EP (1) | EP1545453B1 (de) |
JP (1) | JP2006501310A (de) |
AT (1) | ATE448775T1 (de) |
AU (2) | AU2003268330A1 (de) |
CA (1) | CA2495144A1 (de) |
DE (1) | DE60330161D1 (de) |
ES (1) | ES2339003T3 (de) |
TW (1) | TW200500071A (de) |
WO (1) | WO2004019907A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
CA2536378A1 (en) * | 2003-08-22 | 2005-03-10 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
WO2005058231A2 (en) * | 2003-12-10 | 2005-06-30 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
WO2005062882A2 (en) * | 2003-12-23 | 2005-07-14 | Activbiotics, Inc | Rifamycin analogs and uses thereof |
CA2470090A1 (fr) * | 2004-06-18 | 2005-12-18 | Bio-K Plus International Inc. | Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques |
FR2882522B1 (fr) * | 2005-02-25 | 2007-04-13 | Aventis Pharma Sa | Composition pharmaceutique solide comprenant de la telithromycine |
CN100398546C (zh) * | 2005-06-29 | 2008-07-02 | 上海医药科技发展有限公司 | 碳青霉烯类抗生素法罗培南钠的制备方法 |
WO2007075794A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Oral formulations comprising tigecycline |
BRPI0620430A2 (pt) * | 2005-12-22 | 2011-11-08 | Wyeth Corp | métodos para tratar infecções do trato gastrointestinal com tigeciclina |
US20070248668A1 (en) * | 2006-04-06 | 2007-10-25 | Michaelis Arthur F | Pharmaceutical compositions and uses thereof |
EA017564B1 (ru) | 2007-09-12 | 2013-01-30 | Тарганта Терапьютикс Корп. | Способ ингибирования клостридиум диффициле введением оритаванцина |
MX2011000319A (es) * | 2008-07-07 | 2011-09-29 | Activbiotics Pharma Llc | Uso de rifalazil para tratar trastornos colonicos. |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
BRPI0920465A2 (pt) | 2008-10-02 | 2018-03-20 | Salix Pharmaceuticals, Inc. | metodo de tratamento de encefalopatia hepática |
AU2010213708B2 (en) | 2009-02-11 | 2015-12-10 | Cedars-Sinai Medical Center | Antibody to cytolethal distending toxin of Campylobacter jejuni |
CA2752020A1 (en) * | 2009-02-11 | 2010-08-19 | Cedars-Sinai Medical Center | Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome |
ES2762442T3 (es) * | 2009-10-26 | 2020-05-25 | Borody Thomas J | Novedosa terapia de combinación entérica |
WO2012138963A1 (en) * | 2011-04-06 | 2012-10-11 | The Board Of Regents Of The University Of Texas System | Inositol hexakisphosphate analogs and uses thereof |
MX2015003326A (es) | 2012-09-17 | 2015-08-12 | Cedars Sinai Medical Center | Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia. |
EP3160465A4 (de) | 2014-06-24 | 2017-12-20 | The Board of Trustees of the Leland Stanford Junior University | Verwendung von kleinen molekülen zur behandlung von clostridium-difficile-toxizität |
US20170189444A1 (en) * | 2016-01-06 | 2017-07-06 | California Institute Of Technology | Polymeric compositions and related systems and methods for regulating biological hydrogels |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1304363C (en) * | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
IL98087A (en) * | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
US5266315A (en) * | 1990-05-07 | 1993-11-30 | Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho | Composite for Clostridium difficile diarrhea and pseudomembranous colitis |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
EP0616841B1 (de) * | 1992-10-09 | 1998-12-23 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Herstellungsmethode für feines granulat |
WO1995028963A1 (fr) * | 1994-04-22 | 1995-11-02 | Yamanouchi Pharmaceutical Co., Ltd. | Systeme de liberation de medicament specifique au colon |
US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
WO1996007430A1 (en) * | 1994-09-06 | 1996-03-14 | Galagen, Inc. | Therapeutic treatment of clostridium difficile associated diseases |
FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
EP0998271B3 (de) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
KR100219918B1 (ko) * | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
US6114310A (en) * | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US5968554A (en) * | 1998-07-07 | 1999-10-19 | Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. | Sustained release pharmaceutical preparation |
US6316433B1 (en) * | 1998-12-18 | 2001-11-13 | Kaneka Corporation | Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US6488962B1 (en) * | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
AU2003239919A1 (en) * | 2002-06-03 | 2003-12-19 | Activbiotics, Inc. | Intravenous rifalazil formulation and methods of use thereof |
-
2003
- 2003-08-29 AU AU2003268330A patent/AU2003268330A1/en not_active Abandoned
- 2003-08-29 AT AT03749288T patent/ATE448775T1/de not_active IP Right Cessation
- 2003-08-29 US US10/652,799 patent/US20040106590A1/en not_active Abandoned
- 2003-08-29 DE DE60330161T patent/DE60330161D1/de not_active Expired - Lifetime
- 2003-08-29 TW TW092123881A patent/TW200500071A/zh unknown
- 2003-08-29 CA CA002495144A patent/CA2495144A1/en not_active Abandoned
- 2003-08-29 WO PCT/US2003/027305 patent/WO2004019907A1/en active Application Filing
- 2003-08-29 JP JP2004569768A patent/JP2006501310A/ja active Pending
- 2003-08-29 ES ES03749288T patent/ES2339003T3/es not_active Expired - Lifetime
- 2003-08-29 EP EP03749288A patent/EP1545453B1/de not_active Expired - Lifetime
-
2009
- 2009-10-12 AU AU2009225281A patent/AU2009225281A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60330161D1 (de) | 2009-12-31 |
WO2004019907A1 (en) | 2004-03-11 |
EP1545453A4 (de) | 2005-10-12 |
AU2003268330A1 (en) | 2004-03-19 |
TW200500071A (en) | 2005-01-01 |
CA2495144A1 (en) | 2004-03-11 |
US20040106590A1 (en) | 2004-06-03 |
ES2339003T3 (es) | 2010-05-14 |
EP1545453B1 (de) | 2009-11-18 |
AU2009225281A1 (en) | 2009-10-29 |
JP2006501310A (ja) | 2006-01-12 |
EP1545453A1 (de) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
ATE474592T1 (de) | Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz | |
NO20034056D0 (no) | Proliferative sykdommer | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
ATE541848T1 (de) | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv | |
ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
DE60330146D1 (de) | Verfahren zur reinigung von fibrinogen | |
DE602006009786D1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
ATE359816T1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
DE60326248D1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
DE602005021766D1 (de) | Verfahren zur behandlung von atherosklerose | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
ATE410235T1 (de) | Behandlung von ballastwasser | |
DE60215649D1 (de) | Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
AU2002231777A1 (en) | Use of mglur5 antagonists for the treatment of pruritic conditions | |
ATE350445T1 (de) | Zusammensetzung, ausrüstung und methode zur reinigung und/oder behandlung von oberflächen | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |